Michael Pishvaian, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Amgen
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    RenovoRx
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Boerhinger Ingelheim
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Asellas
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Hutchinson Pharma
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Takeda
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Actuate
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Mei Pharma
    Topic:
    Funding for my Institution
    Date added:
    08/16/2023
    Date updated:
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond